Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for ''
published presentations and documents on DocSlides.
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
When can we use combination therapy for our pediatric IBD p
by pasty-toler
Athos Bousvaros MD, MPH. Advances in IBD Dec 2014...
A patient
by lindy-dunigan
with severe . Crohn's. . disease, an . ileal. s...
What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
JAPIVOL 52MARCH 2004wwwjapiorg231
by stella
Update ArticleBiologics in Rheumatoid ArthritisP K...
Should we change how we position biologics for their use in
by tawny-fly
Stephen B. Hanauer, MD. Professor of Medicine,. N...
Pro: All medications may be stopped for Crohn’s disease p
by briana-ranney
Miguel Regueiro, M.D.. Professor of Medicine. Ass...
Crohn's
by olivia-moreira
disease: diagnosis and management. د. حسين ...
Can Rheumatoid Arthritis treatment ever be stopped?
by celsa-spraggs
Robert L. DiGiovanni, DO, FACOI. Program Director...
Prevention of Postoperative Crohn’s disease
by jane-oiler
Miguel Regueiro, M.D.. Professor of Medicine. Ass...
©2010 MFMER | slide-
by myesha-ticknor
1. Edward V. Loftus, Jr., M.D.. Professor of Medi...
Future comparative effectiveness studies:
by calandra-battersby
unanswered questions. in the care of IBD patient...
PRISME Forum
by giovanna-bartolotta
Ewan Hunter PhD . Director Technical Support EMEA...
Load More...